Key Points
- Insider Andrew Murphy sold 4,147 Regeneron shares for approximately $3.2 million under a pre-arranged Rule 10b5-1 plan, reducing his position by 7.98% while retaining 47,833 shares.
- Regeneron reported strong quarterly results, with EPS of $14.29 beating estimates by $4.13 and revenue rising 16.7% year over year to $4.29 billion.
- Analyst sentiment remains favorable: the stock carries a “Moderate Buy” consensus rating with an average price target of $845.21, while UBS upgraded it to “Buy” with a $978 target.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) insider Andrew Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the completion of the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. This trade represents a 7.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Regeneron Pharmaceuticals Trading Up 2.3%
Shares of Regeneron Pharmaceuticals stock opened at $796.34 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business has a fifty day simple moving average of $791.59 and a two-hundred day simple moving average of $721.30. Regeneron Pharmaceuticals, Inc. has a 1 year low of $564.00 and a 1 year high of $859.34. The company has a market capitalization of $81.99 billion, a price-to-earnings ratio of 19.68, a P/E/G ratio of 1.35 and a beta of 0.16.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the company earned $12.81 earnings per share. The company's quarterly revenue was up 16.7% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.
Regeneron Pharmaceuticals News Summary
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: UBS upgraded Regeneron to “Buy” and raised its price target to $978 from $660, arguing that the market is underestimating the long-term opportunity for Dupixent. The new target implies substantial upside and is the clearest near-term catalyst for investor optimism. Tickerreport UBS upgrade article
- Positive Sentiment: A valuation analysis says Regeneron still appears below fair value after fresh trial data and renewed attention on its immunology alliance. The report suggests the company’s earnings power may not be fully reflected in its current valuation. Regeneron stock fair value article
- Positive Sentiment: Regeneron could benefit from having paid off its balance owed to Sanofi, which had reduced the revenue reported from their partnership. The change may improve the financial contribution from the collaboration going forward. Trefis Regeneron catalysts article
- Positive Sentiment: Analysts expect double-digit bottom-line growth in the upcoming third-quarter report, keeping earnings momentum and the company’s ability to exceed estimates in focus. Barchart Regeneron earnings preview
- Neutral Sentiment: A review of biotechnology-sector results included Regeneron among the companies investors are evaluating, but provided limited new company-specific information. Yahoo Finance biotechnology earnings review
- Negative Sentiment: Director Andrew Murphy sold 4,147 shares worth approximately $3.2 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a limited bearish signal, although it may weigh modestly on sentiment.
Analysts Set New Price Targets
A number of brokerages recently commented on REGN. Raymond James Financial upped their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Morgan Stanley raised their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Evercore boosted their price objective on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Finally, Jefferies Financial Group boosted their price objective on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $845.21.
View Our Latest Research Report on REGN
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Milestone Asset Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $1,252,000. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 780.0% in the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 39 shares during the last quarter. Purus Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $235,000. Mainsail Asset Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $234,000. Finally, B.A. Schrock Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the third quarter worth about $1,608,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.
Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
